Haemonetics (HAE)

Overall impact
C (57)

Commentary

Haemonetics is an average overall performer. With a 'C' rating of 57.0 for overall impact (56th percentile compared to all companies), Haemonetics ranks 73rd out of 103 industry peers, behind Waters, MyMD Pharmaceuticals, Alphatec and 69 others, and ahead of Mesa Laboratories, NeuroMetrix, Tactile Systems Technology and 27 others. On top material causes for Haemonetics's industry (Healthcare Equipment), Haemonetics performs well in Child and Maternal Health (82.5 score) and performs poorly in Racial Justice and Civil Rights (37.4 score).
Impact
Cause HAE
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
3,009
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Ma, United States
Share classes
HAE
Description
Haemonetics Corporation, a medical technology company, provides a suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions. It also provides integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain, as well as the NexLynk DMS donor management system and Donor360 tool. In addition, Haemonetics Corporation provides treatment in various medical fields, including electrophysiology, critical care, neurocritical care, trauma, burn surgery, spine surgery, and cancer surgery, among others. The company offers SavvyWire, a sensor-guided 3-in-1 guidewire for TAVR procedures, and OptoWire, a pressure guidewire that measures fractional flow reserve and diastolic pressure ratio. It also provides fiber optic sensor solutions used in medical devices and other critical industrial applications. The company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis. Additionally, it provides TEG Manager software, which connects various TEG analyzers throughout the hospital, allowing clinicians remote access to active and historical test results that inform treatment decisions. Further, Haemonetics Corporation offers Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries. The company also provides VASCADE closure products, including VASCADE 5F, VASCADE 6/7F, VASCADE MVP XL, and VASCADE MVP, a technology platform that offers a catheter-based delivery system and leverages the natural clot-inducing properties of collagen. Haemonetics Corporation sells its products through a direct sales force, independent distributors, clinical specialists, and sales representatives. The company was founded in 1971 and is headquartered in Boston, Massachusetts.
Material causes
Ethos considers the following causes material for Haemonetics, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.